The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Emerging drugs for the treatment of anxiety
Open accessAbstract
INTRODUCTION: Anxiety disorders are among the most prevalent and disabling psychiatric disorders in the United States and worldwide. Basic research has provided critical insights into the mechanism regulating fear behavior in animals and a host of animal models have been developed in order to screen compounds for anxiolytic properties. Despite this progress, no mechanistically novel agents for the treatment of anxiety have come to market in more than two decades. AREAS COVERED: The current review will provide a critical summary of current pharmacological approaches to the treatment of anxiety and will examine the pharmacotherapeutic pipeline for treatments in development. Anxiety and related disorders considered herein include panic disorder, social anxiety disorder, generalized anxiety disorder and post-traumatic stress disorder. The glutamate, neuropeptide and endocannabinoid systems show particular promise as future targets for novel drug development. EXPERT OPINION: In the face of an ever-growing understanding of fear-related behavior, the field awaits the translation of this research into mechanistically novel treatments. Obstacles will be overcome through close collaboration between basic and clinical researchers with the goal of aligning valid endophenotypes of human anxiety disorders with improved animal models. Novel approaches are needed to move basic discoveries into new, more effective treatments for our patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationBiological studies of post-traumatic stress disorder
Pitman, R. K., Rasmusson, A. M., Koenen, K. C., Shin, L. M., Orr, S. P., Gilbertson, M. W., Milad, M. R., & Liberzon, I. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3339 · Cited by 1,529
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Self-citationStein, M. B., & Stein, D. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60488-2 · Cited by 1,137
Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771 · cited 11×
“A second study found evidence for a beneficial effect of cannabidiol for public speaking in SAD [126].”
BackgroundInfluentialBang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101459g · Cited by 606
Prevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542
Cuijpers, P., Sijbrandij, M., Koole, S. L., Andersson, G., Beekman, A. T., & Reynolds, C. F. (2013) · World Psychiatry · doi:10.1002/wps.20038 · Cited by 540 · cited 1×
“Multiple randomized controlled trials (RCTs) support the efficacy of SSRIs and serotonin norepinephrine reuptake inhibitors (SNRIs) as first-line treatments for GAD, SAD, panic disorder and PTSD [13,16-18].”
Background
Research works printed but not linked: 99
- Schaffer A, 2012, Ann Clin Psychiatry., 24, 6
- 10.1002/da.22214 · DOI
- 10.1038/nrd4075 · DOI · Paper page
- 10.1080/j.1440-1614.2005.01510.x · DOI
- Watanabe N, 2009, Cochrane Database Syst Rev., 1, D005335
- Imai H, 2014, Cochrane Database Syst Rev., 9, D010828
- Stein DJ, 2006, Cochrane Database Syst Rev., 1, D002795
- Kapczinski F, 2003, Cochrane Database Syst Rev., 2, D003592
- 10.1017/S1461145710001434 · DOI · Paper page
- 10.1176/appi.ajp.158.12.1989 · DOI · Paper page
- 10.1001/archpsyc.58.7.681 · DOI
- 10.1002/wps.20087 · DOI · Paper page
- 10.1016/j.janxdis.2012.10.006 · DOI
- 10.1001/jamapsychiatry.2014.2470 · DOI
- 10.1007/s40265-013-0161-9 · DOI
- 10.1016/j.euroneuro.2012.07.012 · DOI
- 10.1016/j.euroneuro.2012.07.011 · DOI
- 10.1002/hup.2371 · DOI
- 10.1097/YIC.0b013e3283530ad7 · DOI
- 10.1517/17460441.2013.855195 · DOI
- Pierz KA, 2014, Prim Care Companion CNS Disord., 16, 10
- 10.1097/YIC.0000000000000045 · DOI
- 10.1016/j.euroneuro.2012.06.016 · DOI
- 10.1038/npp.2009.72 · DOI · Paper page
- 10.1097/JCP.0b013e318184ff5b · DOI · Paper page
- 10.1002/hup.2294 · DOI · Paper page
- De Berardis D, 2013, Int J Immunopathol Pharmacol., 26, 299, 10.1177/039463201302600203 · DOI
- 10.1002/(SICI)1098-2396(199605)23:1<28::AID-SYN4>3.0.CO;2-J · DOI · Paper page
- 10.1002/(SICI)1098-2396(199605)23:1<39::AID-SYN5>3.0.CO;2-I · DOI
- 10.1016/j.ynstr.2014.10.002 · DOI · Paper page
- 10.1176/appi.ajp.158.8.1227 · DOI · Paper page
- 10.1002/da.20292 · DOI · Paper page
- 10.1517/14656566.2014.930437 · DOI
- 10.1176/appi.ajp.163.12.2186 · DOI
- Davis LL, 2008, Psychopharmacol Bull., 41, 8
- 10.1111/acer.12520 · doi:10.1111/acer.12520
- 10.1016/j.jad.2004.11.007 · DOI
- 10.1590/S1516-44462008000400011 · DOI
- 10.1097/JCP.0b013e318224864d · DOI
- 10.1097/YIC.0b013e32834d9f49 · DOI
- 10.4088/JCP.v66n1016 · DOI
- Pandina GJ, 2007, Psychopharmacol Bull., 40, 41
- 10.1001/jama.2011.1080 · DOI · Paper page
- 10.1016/j.clinthera.2007.01.013 · DOI · Paper page
- 10.1001/archpsyc.62.9.1022 · DOI · Paper page
- 10.1097/YIC.0b013e32831d7980 · DOI
- 10.1136/bmj.d1199 · DOI · Paper page
- 10.1176/appi.ajp.160.3.533 · DOI · Paper page
- 10.1097/YIC.0b013e3283466657 · DOI
- 10.1097/01.pra.0000456590.12998.41 · DOI
- 10.1111/epi.12101 · DOI
- Lapidus KA, 2013, Neuropsychiatr Dis Treat., 9, 1101
- 10.1001/jamapsychiatry.2014.62 · DOI · Paper page
- 10.1016/j.biopsych.2012.05.028 · DOI · Paper page
- 10.1038/npp.2013.150 · DOI · Paper page
- 10.1517/13543784.2013.803066 · DOI
- 10.1038/sj.npp.1301531 · DOI · Paper page
- 10.1097/00004850-200511000-00001 · DOI
- 10.1111/bph.12779 · DOI
- 10.1016/j.biopsych.2009.07.036 · DOI · Paper page
- Chalmers DT, 1995, J Neurosci., 15, 6340, 10.1523/JNEUROSCI.15-10-06340.1995 · DOI · Paper page
- 10.1146/annurev.pharmtox.44.101802.121410 · DOI · Paper page
- 10.1016/S0022-3956(98)90056-5 · DOI · Paper page
- 10.1007/BF02244208 · DOI · Paper page
- 10.1016/0018-506X(87)90044-4 · DOI · Paper page
- 10.1016/j.ejphar.2004.12.030 · DOI
- Baker DG, 1999, Am J Psychiatry., 156, 585, 10.1176/ajp.156.4.585 · DOI · Paper page
- 10.1016/j.ejphar.2007.12.032 · DOI · Paper page
- 10.1002/da.20695 · DOI · Paper page
- 10.1016/j.bmcl.2010.10.095 · DOI
- 10.1002/emmm.201000100 · DOI · Paper page
- 10.1517/14728222.2011.628314 · DOI · Paper page
- 10.1016/j.biopsych.2014.01.009 · DOI
- 10.1016/j.biopsych.2013.11.012 · DOI
- 10.1016/j.npep.2004.05.002 · DOI · Paper page
- 10.1016/j.neuroscience.2013.01.040 · DOI · Paper page
- 10.1016/S0006-3223(99)00185-7 · DOI · Paper page
- 10.1016/j.biopsych.2005.08.027 · DOI · Paper page
- 10.1016/j.biopsych.2009.04.037 · DOI
- 10.1016/j.psyneuen.2013.10.017 · DOI
- 10.1126/science.281.5383.1640 · DOI · Paper page
- 10.1038/npp.2008.176 · DOI
- 10.1007/s11307-005-7001-6 · DOI
- 10.2165/00023210-200519040-00001 · DOI
- 10.1007/s00726-006-0335-9 · DOI · Paper page
- 10.1176/appi.ajp.163.4.637 · DOI
- 10.1016/j.euroneuro.2010.11.012 · DOI
- 10.1016/j.euroneuro.2009.10.005 · DOI
- 10.1016/j.neubiorev.2005.05.008 · DOI
- 10.1001/archpsyc.1989.01810060031006 · DOI · Paper page
- 10.1038/npp.2008.97 · DOI
- 10.1016/j.bbi.2014.06.007 · DOI
- 10.1016/0166-2236(90)90124-S · DOI · Paper page
- 10.3389/fnbeh.2011.00063 · DOI
- 10.1007/s40261-014-0212-3 · DOI · Paper page
- 10.1002/hup.1048 · DOI · Paper page
- 10.1590/S1516-44462009000200012 · DOI · Paper page
- 10.1016/j.pharmthera.2012.12.002 · DOI · Paper page
- 10.1016/j.tins.2011.06.007 · DOI · Paper page
Cited by
Craske, M. G., Stein, M. B., Eley, T. C., Milad, M. R., Holmes, A., Rapee, R. M., & Wittchen, H.-U. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.24 · Cited by 652
Cimino, C., Maurel, O. M., Musumeci, T., Bonaccorso, A., Drago, F., Souto, E. M. B., Pignatello, R., & Carbone, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030327 · Cited by 324
A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)
Peng, J., Fan, M., An, C., Ni, F., Huang, W., & Luo, J. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13710 · Cited by 282
Sartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
The P2X7 Receptor: Central Hub of Brain Diseases
Andrejew, R., Oliveira-Giacomelli, Á., Ribeiro, D. E., Glaser, T., Arnaud-Sampaio, V. F., Lameu, C., & Ulrich, H. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00124 · Cited by 162
Metadata
- Authors
- Murrough, J. W., Yaqubi, S., Sayed, S., & Charney, D. S.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa UK Limited
- Published
- 2015-05-26
- Volume
- 20
- Issue
- 3
- Pages
- 393-406
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W1744121855
- Cited by
- 164
- References
- 32
- FWCI
- 11.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging drugs for the treatment of anxiety. https://app.cochat.ai/papers/10.1517/14728214.2015.1049996
- The paper
- Murrough, J. W., Yaqubi, S., Sayed, S., & Charney, D. S. (2015). Emerging drugs for the treatment of anxiety. Expert Opinion on Emerging Drugs. https://doi.org/10.1517/14728214.2015.1049996
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.